Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,511 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05376592Recruiting
Study genes and weight loss in pancreatic cancer
This study looks at how a person’s genetic variations may relate to cancer-related weight loss (cachexia) in pancreatic cancer. It may help researchers better understand who is most at risk and guide future treatments.
Charlotte, North CarolinaAges 18 years+ - NCT05389293RecruitingPhase 2
Mosunetuzumab with or without zanubrutinib for follicular lymphoma
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05384496RecruitingPhase 2
Axitinib and nivolumab for advanced mucosal melanoma
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
Harrison, New YorkAges 18 years+ - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75 - NCT07705438Recruiting
PET scan to predict if immunotherapy works in TNBC
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
ShanghaiAges 18 years+ - NCT07705243RecruitingPhase 3
Maintenance therapy for advanced nasopharyngeal cancer
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Guangzhou, GuangdongAges 18–75 - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05342194RecruitingPhase 3
Testing an immunotherapy plus chemo for advanced bile duct cancer
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05281406RecruitingPhase 2
Extra chemotherapy if tumor DNA stays positive after osimertinib
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
BerlinAges 18 years+ - NCT05264896RecruitingPhase 3
Stomach cancer surgery plus two chemo plans
This trial compares two chemotherapy schedules around stomach cancer surgery: giving chemo before and after surgery (FLOT) versus giving chemo after surgery (XELOX). It’s meant to see which plan works better and is easier to tolerate for locally advanced disease that has not spread.
Hong KongAges 18 years+ - NCT05306132RecruitingPhase 1
Test drug ASKC202 for advanced lung cancer and MET-positive tumors
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
Zhengzhou, HenanAges 18 years+ - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05217693RecruitingPhase 1
First study drug BB-1705 for advanced solid tumors
This Phase 1 trial tests BB-1705 in people with advanced or metastatic (spread) solid tumors that cannot be removed with surgery. It mainly focuses on safety and how the drug behaves in the body, and may offer an option for patients when standard treatments have not worked.
BeijingAges 18–78 - NCT05197881Recruiting
Daily adaptive radiation for newly diagnosed cervical cancer
This study tests a radiation plan that is adjusted day by day to better match your cervix and surrounding tissues during treatment. It’s for newly diagnosed, advanced cervical cancer patients who will receive standard pelvic radiation and chemotherapy.
Burmingham, AlabamaAges 18 years+ - NCT05254327RecruitingPhase 2
Radiation plus or minus BMX-001 for advanced rectal cancer
This Phase 2 study tests two different ways of giving radiation before surgery for locally advanced rectal cancer, with or without an added study drug called BMX-001. It aims to see whether the shorter/longer radiation plans and BMX-001 improve cancer control and are safe.
Lexington, KentuckyAges 18 years+ - NCT05230134Enrolling by invitation
Nerve block treatment for brain blood vessel spasm after bleeding
This trial looks at a procedure that blocks specific nerves to help prevent or treat blood vessel spasm in the brain after a ruptured brain aneurysm. If you qualify, it may help improve blood flow to the brain during recovery in the ICU.
Stanford, CaliforniaAges 18 years+ - NCT05180864Recruiting
Omentum saving surgery versus full removal in stomach cancer
This study compares two ways of doing surgery for gastric (stomach) cancer: saving the omentum versus removing it completely. It may help doctors learn which approach is safer and works better for cancer control and recovery.
MainzAges 18 years+ - NCT05196334Recruiting
Testing pancreatic lab samples to guide future treatments
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
Herlev, CopenhagenAges 18 years+ - NCT05132504RecruitingPhase 2
Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Houston, TexasAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT04982276RecruitingPhase 1/Phase 2
Test new cancer drugs for advanced stomach or esophagus cancer
This Phase 1/2 study tests the safety and effectiveness of two investigational drugs (AK109 and AK104) in people with advanced stomach (or lower esophagus/GEJ) cancer. It’s for cases where the cancer did not respond to first-line treatment that included anti–PD-1/PD-L1 therapy plus chemotherapy.
BeijingAges 18–75 - NCT07307456RecruitingPhase 2
Toripalimab and BCG for high-risk bladder cancer
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04992559RecruitingPhase 2
Toripalimab after surgery and chemoradiation for head and neck cancer
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
Guangzhou, GuangdongAges 18–70
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,511 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.